Lumos Diagnostics Holdings Ltd
Company Profile
Business description
Lumos Diagnostics Holdings Ltd is engaged in selling Products and providing Services to customers. Its product offering includes rapid, point-of-care diagnostic test products, mainly focused on the diagnosis and management of infectious diseases. Its product is FebriDx, a point-of-care test for detecting and differentiating viral and bacterial respiratory infections. Its Service offering includes contract research and development services specialising in innovation, development, manufacturing and commercialisation of point-of-care diagnostic test solutions. The Company has one operating segment, being the provision of point-of-care diagnostics goods and services. It operates in the United States and Australia, with the majority of revenue generated from the United States.
Contact
2724 Loker Avenue West
CarlsbadCA92010
USAT: +1 855 586-6739
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.70 | 5.10 | 0.06% |
| CAC 40 | 8,107.91 | 30.11 | 0.37% |
| DAX 40 | 25,464.97 | 56.33 | 0.22% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,739.41 | 44.16 | 0.41% |
| HKSE | 24,647.55 | 137.46 | 0.56% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 65,877.62 | 486.59 | -0.73% |
| NZX 50 Index | 13,830.68 | 19.57 | 0.14% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,679.70 | 14.70 | 0.17% |
| SSE Composite Index | 3,823.62 | 64.75 | -1.67% |